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2ABSTRACT 
Objective - To investigate if statins prevent cartilage degradation and the production of collagenases 
and gelatinases in bovine nasal and human articular cartilage after pro-inflammatory cytokine 
stimulation.  
Methods - In a cartilage degradation model, the effect of a number of statins were assessed by 
measuring proteoglycan degradation and collagen degradation, while collagenolytic and gelatinolytic 
activity in culture supernatants were determined by collagen bioassay and gelatin zymography. The 
production of MMPs in cartilage and chondrocytes were analysed by real-time RT-PCR and 
immunoassay. Cytokine-induced signalling pathway activation was studied by immunoblotting. 
Results - Simvastatin and mevastatin significantly inhibited IL-1+OSM-induced collagen degradation; 
this was accompanied with a marked decrease in collagenase and gelatinase activity from bovine nasal 
cartilage. The cholesterol pathway intermediate mevalonic acid reversed the simvastatin-mediated 
protection of cartilage degradation, and the expression and production of collagenase (MMP-1 and -
13), and gelatinase (MMP-2, and -9). Statins also significantly decreased MMP-1 and MMP-13 
expression in human articular cartilage and chondrocytes stimulated with IL-1+OSM, and blocked the 
activation of critical pro-inflammatory signalling pathways required for MMP expression. The loss of 
the isoprenoid intermediate geranylgeranyl pyrophosphate due to statin treatment accounted for the 
inhibition of MMP expression and signalling pathway activation. 
Conclusion - This study showed, for the first time, that lipophilic statins are able to block cartilage 
collagen breakdown induced by pro-inflammatory cytokines, by down regulating key cartilage 
degrading enzymes. This demonstrates a possible therapeutic role for statins in not only acting as anti-
inflammatory agents but also in protecting cartilage from damage in joint diseases.
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3INTRODUCTION 
Cartilage covers the articulating joint surface allowing free movement and is composed predominately 
of an extracellular matrix (ECM) containing proteoglycan (aggrecan) and collagen (predominantly 
type II collagen). Irreversible progressive loss of the cartilage matrix is a major feature in both 
rheumatoid arthritis (RA) and osteoarthritis (OA), which ultimately leads to the loss of joint function. 
Within this ECM chondrocytes control the turnover and remodelling of the cartilage matrix, by 
regulating the expression of matrix components and matrix degrading enzymes.[1] Pro-inflammatory 
cytokines such as interleukin-1α (IL-1) and tumour necrosis factor α (TNFα) are considered as key 
pathogenic molecules in this process. Their action, especially when in combination with  oncostatin M 
(OSM), a member of the IL-6 cytokine family, leads to an up-regulation of a number of 
metalloproteinases, a family of zinc dependent endopeptidases that includes the matrix 
metalloproteinases (MMPs) and the ‘a disintegrin and metalloproteinase with thrombospondin motifs’ 
(ADAMTSs) which together have the ability to break down all ECM components.[2] Aggrecan is 
degraded by both MMPs and ADAMTSs, whereas type II collagen is degraded by MMPs, including 
MMP-1, -8, -13, and -14. Following this cleavage gelatinases such as MMP-2 and MMP-9 and the 
stromelysin MMP-3 are able to further degrade collagen, while MMP-3 also has an important role in 
the activation of pro-collagenases and pro-gelatinases.[3] Together, these proteases release specific 
aggrecan or collagen II fragments that can be measured in vitro and in vivo.[4] Loss of aggrecan from 
cartilage is reversible whilst collagen breakdown is not and therefore represents an irreversible step in 
cartilage degradation.[5, 6] 
Statins are the most commonly prescribed drugs for the prevention of cardiovascular diseases. They 
represent a group of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and 
thus reduce serum cholesterol levels by inhibiting the cholesterol biosynthesis pathway.[7] Statin 
inhibition of HMG-CoA reductase prevents the catalyzation of HMG-CoA to mevalonic acid (MA), 
the rate limiting step in the biosynthesis of cholesterol and the pathway intermediates such as the 
isoprenoids farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) which are 
involved in protein prenylation.[8] Statins also possess anti-inflammatory properties and immuno-
modulatory actions that are unrelated to their lipid-lowering abilities and may be a result of the loss of 
protein prenylation.[9] The isoprenoid intermediates are conjugated post-translationally to specific 
CAAX motif containing proteins, in particular GTPases such as Ras, Rac and Rho family members, 
which have crucial roles in controlling many signalling pathways.[10, 11]  
As a result of these anti-inflammatory actions statins have emerged as a class of drugs with potential 
for the treatment of rheumatic disorders, including RA. A small number of trials have attempted to 
address this, although only modest effects have been found so far and with qualifications.[9, 12] In 
4animal models several studies have demonstrated that statins might inhibit the severity and 
progression of arthritis.[13-15] In addition to their disease modifying activity, statins reduced the 
inflammatory cell infiltration into the synovium and down-regulated pro-inflammatory cytokine 
levels.[13-15] However, another study found no effect of a number of statins in a murine model of 
arthritis.[16] 
We have previously reported that IL-1 or TNFα in combination with OSM synergistically induces 
cartilage degradation by up-regulating MMPs, especially the collagenases MMP-1 and MMP-13, both 
in vitro and in vivo.[17-19] Statins have been studied in detail in the cardiovascular field and have 
been demonstrated to reduce MMP production.[20-22] Statins can also block IL-1-induced MMP-3 in 
chondrocytes,[23] and protein prenylation regulates IL-1 or TNFα-induced MMP-1 expression in 
rheumatoid synovial fibroblasts.[24] However, no study has examined the ability of statins to prevent 
cartilage collagen breakdown, the critical pathological step in arthritic diseases. Therefore, in the 
present study, we investigate whether statins are able to directly protect cartilage against breakdown 
induced by pro-inflammatory cytokines, and if so, then to determine the mechanisms involved in the 
regulation of cartilage breakdown and chondrocyte MMP expression by statins. 
5MATERIALS AND METHODS 
Materials - All cytokines used were recombinant human. IL-1α was a generous gift from Dr. Keith 
Ray (Glaxo-SmithKline, Stevenage, UK). OSM was kindly donated by Prof. John Heath (Department 
of Biochemistry, University of Birmingham, Edgbaston, UK). Simvastatin, mevastatin, fluvastatin and 
pravastatin sodium salts were purchased from Merck Chemicals (Nottingham, UK). Mevalonic acid, 
squalene, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) were from Sigma-
Aldrich (Poole, UK). Primary antibodies used were phospho-ERK1/2 (phospho-p44/42) (#9101), 
phospho-p38 (#9211), phospho-JNK (#9251), phospho-Akt (Ser473; #9271) and IκBα (#9242) from 
Cell Signaling Technology (Danvers, USA). A mouse monoclonal anti-glyceraldehyde 3’-phosphate 
dehydrogenase (GAPDH) antibody (clone 6C5; MAB374) was purchased from Chemicon 
(Hampshire, UK). The polyclonal secondary immunoglobulins/HRP were from Cytomation (Dako, 
Glostrup, Denmark).  
Cartilage assays - Bovine nasal septum cartilage and human articular cartilage were dissected into  2
× 2 × 2-mm discs, plated into 24-well tissue culture plates (3 discs per well, n = 4) and cultured in 
serum-free DMEM medium as described.[25] Fresh serum-free media ± cytokines + test reagents were 
then added (day 0). At day 7, culture supernatants were harvested and replaced with fresh medium 
containing the same test reagents as day 0. Cartilage and culture supernatants were harvested at day 14 
and the remaining cartilage was digested with papain. Hydroxyproline release was assayed as a 
measure of collagen degradation,[26] and glycosaminoglycan release assayed as a measure of 
proteoglycan degradation.[27] The extent of release was calculated as a percentage of the total. In a 
separate experiment culture supernatants were harvested at day 3 to assess early glycosaminoglycan 
release. Collagenase activities in the culture supernatants were determined by the 3H-acetylated 
collagen diffuse fibril assay with aminophenylmercuric acetate (APMA) (0.67mM) to activate pro-
collagenases.[28] Gelatinase activity in the culture supernatants was assayed by gelatin 
zymography.[29] The culture supernatants were also assayed by specific immunoassay for MMP-
1[30]  and MMP-13.[31] 
Cell culture - Human articular chondrocytes (HACs) were derived from articular cartilage obtained 
from consented patients following hip or knee replacement surgery with Ethical Committee approval 
from the Newcastle and North Tyneside Health Authority. Enzymatic digestion of tissue and 
maintenance and culture of cells were as previously described.[17] When cells reached 80-90% 
confluence without passage they were pre-treated with test reagents for the indicated time-points after 
which cells were serum-starved for 16 hours prior to stimulation with cytokines for the indicated 
duration.  
6Cell viability - Viability of cartilage explants was assessed by screening for the production of lactate 
dehydrogenase (LDH) using the Cytotox 96 assay (Promega, Southampton, UK). Viability of HACs 
was assessed by screening for the production of adenylate kinase using the ToxiLight BioAssay Kit 
(Lonza, Rockland, ME, USA). 
RNA extraction from cartilage and chondrocytes - RNA was extracted from control and IL-1+OSM-
stimulated cartilage at day 7 of the cartilage degradation assay. Cartilage was ground in a SPEX 
CertiPrep 6750 freezer mill (Glen Creston, Stanmore, UK) and total RNA was isolated from the 
powdered cartilage essentially as described [29] with the use of TRIzol reagent (Invitrogen, Paisley, 
UK) and RNeasy Mini kit, including an on-column DNAse I digestion (Qiagen, Crawley, UK). cDNA 
was synthesized from 1µg of total bovine cartilage RNA, using Superscript II reverse transcriptase and 
random hexamers in a total volume of 20µl according to the manufacturer's instructions (Invitrogen). 
From cultured HACs, total RNA was isolated and reverse transcribed using the ABI Cells-to-cDNA II 
Kit (Applied Biosystems, CA, USA).
Real-time RT-PCR - Oligonucleotides and PCR Mastermix were purchased from Sigma-Genosys 
(Poole, UK), while TaqMan primer/probes were from Applied Biosystems (Foster City, California, 
USA) as previously described.[29, 32] Relative quantitation of genes was performed using the ABI 
Prism 7900HT sequence detection system (Applied Biosystems). Bovine metalloproteinase expression 
profiles were determined using SYBR Green (Takara, Cambrex, Wokingham, UK) in accordance with 
the manufacturer's suggested protocol and as described.[29] The 18S rRNA gene was used as an 
endogenous control to normalise for differences in the amount of total RNA present in each sample. 
Probe based MMP-1, MMP-13 and 18S assays were performed using TaqMan mastermix reagents 
(Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer's protocol and as previously 
reported.[32]  
Immunoblotting - Cells were lysed with ice-cold buffer (50mM Tris-Cl, pH 7.5; 1.2M glycerol; 1mM 
EGTA; 1mM EDTA; 1mM Na3VO4; 10mM β-glycerophosphate; 50mM NaF; 5mM sodium 
pyrophosphate; 1% (v/v) Triton X-100; 1µM microcystin-LR; 0.1% (v/v) β-mercaptoethanol; Roche 
protease inhibitor complex), particulate matter removed by centrifugation at 13,000g, 5 min at 4oC,
and lysates stored at -80ºC until use. Lysates were resolved by SDS-PAGE, transferred to PVDF 
membranes (Millipore, Watford, UK) and subsequently probed using the antibodies described above. 
The quantitation of protein levels was performed with Adobe Photoshop CS (San Jose, CA) using the 
following method: https://www.lukemiller.org/journal/2007/08/quantifying-Western-blots-
without.html.
7Statistical analyses - Statistical differences between sample groups were assessed using the two-tailed 
Student’s t-test, where *, p<0.05; **, p<0.01; and ***, p<0.001. For quantification of immunoblots 
statistical differences between IL-1+OSM treatment and other treatment groups were assessed using 
the one-sample Student’s t-test, where *, p<0.05; and †, p<0.01. 
8RESULTS 
Effect of statins on the release of collagen from bovine nasal cartilage treated with IL-1+OSM. 
Previous studies have shown that IL-1 in combination with OSM can reproducibly stimulate the 
release of both proteoglycan and collagen from bovine nasal cartilage in explant culture by day 7 and 
14 respectively.[17, 18, 33] Using this established model of cartilage destruction, we studied whether 
statins have a direct effect on cartilage degradation. Bovine nasal cartilage discs were cultured in 
control and IL-1α and OSM-containing media in the presence of mevastatin, simvastatin, fluvastatin, 
or pravastatin. After 14 days stimulation, IL-1+OSM induced over 80% collagen release from bovine 
nasal cartilage. Treatment with simvastatin or mevastatin significantly blocked IL-1+OSM-induced 
collagen release (Fig. 1A). Collagen release from TNFα+OSM treated cartilage was also similarly 
inhibited by simvastatin (data not shown). Fluvastatin also reduced collagen release, whereas the 
addition of pravastatin had no effect on the release of collagen. A concentration-dependent decrease in 
cartilage collagen degradation was observed with increasing concentrations of simvastatin and 
mevastatin (Fig. 1B). This was accompanied by reduced total and active collagenase activity (Fig. 1C). 
Statin treatment had no effect on the proteoglycan release from IL-1+OSM-stimulated bovine cartilage 
on day 7 (Supp. Fig. 1A). Furthermore, simvastatin pre-treatment for 3 days prior to IL-1+OSM 
treatment had no effect on day 3 proteoglycan release (Supp. Fig. 1B). Neither mevastatin or 
simvastatin affected the release of LDH from cartilage showing that, at the concentrations used, statins 
are not toxic to the chondrocytes (data not shown). 
Simvastatin and mevastatin prevent pro-inflammatory cytokine-induced collagenase production in 
human articular cartilage. To determine if statins are also able to protect human cartilage we 
measured the production of the collagenases, MMP-1 and MMP-13, following treatment of human 
articular cartilage explants with IL-1+OSM in the presence of a range of concentrations of simvastatin 
and mevastatin for 14 days. Levels of MMP-1 and MMP-13 in the culture supernatant were markedly 
elevated by IL-1+OSM and reduced by both simvastatin and mevastatin in a concentration-dependent 
manner (Fig. 2A and B).  
Mevalonic acid reversed the inhibition of cytokine-induced cartilage breakdown and MMP activity by 
simvastatin in bovine nasal cartilage. Focussing on the clinically relevant statin simvastatin, we 
sought to examine the mechanism by which statins prevent cartilage breakdown and block collagenase 
expression. Statins inhibit the enzyme HMG-CoA reductase, preventing mevalonic acid (MA) 
synthesis (Fig. 3A). MA is converted to cholesterol via the production of a number of intermediates 
including those required in protein prenylation, all of which are depleted following statin treatment. 
We studied the effect of addition of MA and the isoprenoids FPP and GGPP (underlined in Fig. 3A) in 
combination with simvastatin. MA fully reversed the effect of low concentrations of simvastatin (3 
9µM) on cartilage degradation, and partially reversed the effect of the higher concentration of 
simvastatin (10 µM). Again, in collagenolytic assays using day 14 conditioned media from the 
cartilage degradation assay MA reversed the inhibitory effects of simvastatin (Fig. 3C) on IL-1+OSM-
induced collagenase activity and expression. By gelatin zymography, IL-1+OSM resulted in the 
abundant release of active MMP-2 and MMP-9 into the conditioned media and this was significantly 
reduced following treatment with simvastatin and reversed upon addition of MA (Fig. 3D). These 
results indicated that the chondro-protection by statins is a result of the prevention of MA synthesis. 
MA reversed the effect of simvastatin on the inhibition of cytokine-induced MMP expression in bovine 
cartilage. We also investigated whether simvastatin blocked the expression of these key cartilage 
degrading MMPs in bovine cartilage. Bovine cartilage was stimulated with IL-1+OSM in the presence 
of simvastatin ± MA for 7 days, after which total RNA was extracted and the expression of MMP-1, -
3, -9 and -13 assayed by RT-PCR. Simvastatin almost completely blocked IL-1+OSM-induced MMP-
1 and MMP-13 expression and significantly decreased MMP-3 and MMP-9 expression (Fig. 4). 
Addition of MA partially reversed the down-regulation of MMP-1, MMP-3 and MMP-13 by 
simvastatin, but had no effect on the expression of MMP-9. 
Loss of isoprenoid intermediates causes the simvastatin-mediated down-regulation of MMP 
expression in cytokine stimulated human chondrocytes. To further determine the mechanism by which 
simvastatin blocked cartilage breakdown and MMP expression we assessed its effect in cultured 
primary HACs. HACs were pre-treated with simvastatin for 0-72 hours then stimulated with IL-
1+OSM for 24 hours and the expression of MMP-1 and MMP-13 was assayed by real-time RT-PCR. 
Pre-treatment of HACs with simvastatin for 48 and 72 hours significantly down-regulated the 
expression of MMP-1 and MMP-13 induced by IL-1+OSM, whereas simvastatin pre-treatment for 0 
and 24 hours had no effect (Fig. 5A). Cell viability, assessed by measuring adenylate kinase release, 
was unaffected by statin pre-treatment (data not shown). Having established that 48 hours statin pre-
treatment was required, HACs were then incubated with the cholesterol biosynthesis pathway 
intermediates in combination with simvastatin. Incubation with MA reversed the simvastatin-mediated 
inhibition of MMP expression (Fig. 5B). GGPP, and to a lesser extent FPP, also reversed the inhibition 
of MMP expression by simvastatin, suggesting that both geranylgeranylation, and to a lesser extent 
farnesylation, of proteins is required for IL-1+OSM induction of MMP expression. In contrast, 
squalene had no effect on the simvastatin-mediated inhibition of MMP expression suggesting that this 
repression is not mediated by a loss of cholesterol synthesis. We also treated HACs with methyl-β-
cyclodextrin, to remove cholesterol from the cell membrane,[34] and found that this had no effect on 
the induction of MMP expression by IL-1+OSM (data not shown). 
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Effect of simvastatin on the cytokine-activation of signalling pathways in HACs. The pro-inflammatory 
cytokine induction of MMP expression in chondrocytes is mediated by the activation of a number of 
signalling pathways, in particular the MAPK, NF-κB and PI3K/Akt pathways.[35, 36] The activation 
of these signalling pathways is regulated by small GTPases, which require prenylation by the 
pyrophosphate intermediates FPP and GGPP for their cell membrane-localised activity.[10, 11] 
Accordingly, we characterised the effect of simvastatin on the activation of signalling pathways by IL-
1+OSM. Simvastatin treatment downregulated the activation of ERK, p38 and JNK in a concentration-
dependent manner. Simvastatin also partially prevented IkBα degradation and significantly blocked 
the activation of Akt (Fig. 6A and B). To examine the mechanism we then incubated HACs with 
simvastatin in the presence of the cholesterol biosynthesis pathway intermediates. Consistent with its 
requirement in IL-1+OSM-induced cartilage degradation and MMP expression MA reversed the 
simvastatin-mediated inhibition of signalling pathway activation (Fig. 6C and D). GGPP also reversed 
the inhibition while FPP had no effect, suggesting that geranylgeranylation of proteins is necessary for 
the IL-1+OSM activation of signalling pathways in chondrocytes that mediate MMP expression. 
11
DISCUSSION 
This study is the first to demonstrate that the lipophilic statins simvastatin and mevastatin directly 
protect cartilage from cytokine-mediated breakdown by preventing the upregulation in expression and 
production of collagen-degrading MMP-1 and MMP-13. This protective effect is mediated through the 
blocking of HMG-CoA reductase MA generation and as a result reduced synthesis of the prenylation 
intermediate GGPP. 
Statins, as widely used plasma cholesterol-lowering drugs have also been shown to have 
beneficial effects on a wide range of other conditions including atherosclerosis, nephropathy, bone 
disease, diabetes and cancer.[37] RA patients have increased vascular risk and cardiovascular 
mortality and several clinical reports have suggested that statin treatment of RA patients has a 
beneficial effect on disease activity, swollen joint count, endothelial dysfunction, and arterial stiffness 
all linked with an improvement in markers of inflammation.[38] In terms of OA, there are some 
epidemiological data supporting a link between OA and vascular disease,[39] and OA is associated 
with mild inflammation,[40] which taken together suggests that OA patients may benefit from statin 
treatment. 
Laboratory studies on the effect of statins in arthritis have focussed on anti-inflammatory and 
immuno-modulatory actions. Atorvastatin prevented joint inflammation in rat inflammatory arthritis 
with decreased tissue concentrations of IL-1β, IL-6, TNF-α and chemokines.[41, 42] Statins also 
reduced the proportion of IFN-γ release by T-cells and down-regulated expression of inflammatory 
cytokines by synoviocytes in RA.[13-15] In a murine collagen-induced arthritis model, simvastatin 
inhibited the progression of disease, even after the onset of arthritis and suppressed Th-1 responses 
and IFN-γ release.[14] Mevastatin reduced cartilage degradation in a rabbit experimental OA model 
through inhibition of synovial inflammation with lowered expression of IL-1β, MMP-3, MMP-13 and 
monocyte chemoattractant protein-1 in synovial tissues, but not in cartilage.[13] Statins can also 
induce RA synoviocytes to apoptose by the depletion of protein geranylgeranylation and loss of RhoA 
kinase activity.[43, 44] 
In this study we tested several clinically available statins and found that simvastatin, which 
accounts for approximately two-thirds of all UK statin prescriptions,[45] and mevastatin, significantly 
prevented the pro-inflammatory cytokine IL-1+OSM-induced collagen degradation in bovine nasal 
cartilage. The action of both simvastatin and mevastatin was concentration-dependent and was 
accompanied by a marked reduction in total and active collagenase and gelatinase activity. Mevastatin 
and simvastatin are lipophilic statins, which cross membranes non-selectively by passive diffusion, 
whereas pravastatin, a non-lipophilic statin, does not easily cross membranes.[46] Fluvastatin has 
intermediate physico-chemical properties and this was clearly reflected in our data with fluvastatin 
showing partial inhibition of cartilage degradation, whereas pravastatin had no effect. In contrast to 
collagen degradation statins were unable to prevent IL-1+OSM-induced proteoglycan degradation 
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(Supp. Fig. 1). It is possible that different mechanisms are involved in the activation of aggrecanase 
and collagenase activity, or that the cytokine combination used is more potent in inducing 
proteoglycan degradation than collagen. Interestingly, simvastatin inhibited ADAMTS-5 expression 
but had no significant effect on ADAMTS-4 (Supp. Fig. 2). In murine arthritis ADAMTS-5 is reported 
to be the major aggrecanase but it is not known which is the major aggrecanase in bovine nasal 
cartilage or human disease.[47, 48]  
Simvastatin significantly blocked MMP mRNA expression in bovine cartilage and statins also 
decreased the production of these MMPs in human OA articular cartilage and chondrocytes. This 
suggests that the chondro-protective effect of statins in cartilage is mainly mediated by down-
regulation of proteolytic enzymes, especially the collagenases. Throughout, the effects of statins were 
more profound on the cytokine-induced levels of MMP-13 as apposed to MMP-1. MMP-13 is more 
active against type II collagen than MMP-1,[49] and is considered the primary collagenase driving 
degradation of cartilage collagen in osteoarthritis.[50] 
Statins inhibit cholesterol synthesis at the level of the formation of MA and, as a consequence, 
also inhibit the production of various intermediates of the cholesterol biosynthesis pathway, including 
pyrophosphates required in the prenylation of GTPases.[8, 10] To investigate the cellular mechanism 
of statins on cartilage protection, we studied the role of these pathway intermediates in simvastatin 
mediated chondro-protection. MA reversed the effect of simvastatin on cartilage degradation, on 
simvastatin-inhibited active and total collagenase and gelatinase activity in cultured media, and on 
bovine and human MMP mRNA expression. 
Previously, studies have found the activation of MAPK, NF-κB and PI3K/Akt pathways by 
inflammatory cytokines such as IL-1, TNFα and OSM are highly involved in regulation of MMPs 
especially MMP-1 and MMP-13 expression in cartilage.[32, 35, 36] In this study, using human OA 
articular chondrocytes to study the effect of statins on signalling pathways known to be regulated 
during an inflammatory response, we demonstrated that simvastatin treatment prevented the IL-
1+OSM activation of MAPK, NF-κB and PI3K/Akt pathways. Furthermore, we found that the 
inhibition of signalling pathway activation was mediated by the loss of protein geranylgeranylation, as 
addition of GGPP negated the effect of simvastatin. Cholesterol itself is also involved in cell signalling 
where it is found concentrated in lipid raft areas of the cell membrane in association with protein 
signalling complexes.[51] However, addition of squalene was unable to reverse the inhibition of 
signalling pathways by simvastatin and the removal of cholesterol from the cell membrane by 
treatment with methyl-β-cyclodextrin had no effect on IL-1+OSM induced MMP expression. 
It must be considered that the concentrations used to assess the effects of statins in the 
cartilage and chondrocyte cell cultures in this study are higher than clinically prescribed plasma 
concentrations which range between 0.1-1µM for fluvastatin and 10 fold less for other statins.[52] The 
statin concentrations used herein are identical to those routinely used to study their effect in in vitro
cell studies.[20-24] These concentrations may be necessary due to the greater activation of cells in 
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vitro. In vivo the sustained lower plasma levels of statins might have a similar effect over time to those 
seen with the higher concentrations and shorter time periods used in vitro. Only a single trial has been 
published assessing statin use in osteoarthritis and this actually associated the use of statins with 
increased risk of developing hip OA in females, although this could be due to other compounding 
factors. However, in the same study statins showed a trend toward a decreased risk of hip OA 
progression.[53] The higher concentrations required to show efficacy in in vitro studies may explain 
why a significant effect has yet to be found in such trials. Accordingly, further studies are required to 
assess the impact of long term statin administration in patients with arthritic diseases. 
This is the first report to show that statins are able to directly prevent cytokine-induced 
cartilage collagen breakdown by reducing the expression and production of collagenases and 
gelatinases. MA in cartilage and both MA and GGPP in chondrocytes reversed the effects of 
simvastatin indicating that the protective effect of simvastatin on cartilage is mainly through the 
prevention of protein geranylgeranylation. These findings suggest that statins can directly protect 
against cartilage damage and, given their well established anti-inflammatory and immuno-modulatory 
role, have potential as therapeutic agents for both inflammatory and non-inflammatory forms of 
arthritis.
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FIGURE LEGENDS 
Figure 1. The effect of statins on pro-inflammatory cytokine-induced collagen release, 
collagenolytic activity and gelatinolytic activity in bovine cartilage. Bovine nasal cartilage was 
cultured in serum-free medium in the presence of either medium alone, or medium containing IL-1α
(0.5ng/ml) + OSM (10ng/ml) ± (A) the indicated statins at 10µM, (B) simvastatin (Sim) or (B & C) 
mevastatin (Mev) at the indicated concentrations for 14 days. (A & B) The levels of collagen 
fragments released into the medium were determined by measurement of hydroxyproline as described 
in Materials and Methods. Results shown are for the cumulative collagen release at day 14 of culture 
and expressed as a percentage of the total (mean ± S.D). (C) The levels of pro- and active collagenase 
activity in the media from cultured cartilage at day 14 were measured as described in Materials and 
Methods (mean ± S.D). All assays were performed in quadruplicate. Significance was analysed with 
respect to IL-1+OSM with statin compared to IL-1+OSM alone, where * p < 0.05, ** p < 0.01, *** p
< 0.001. Data are representative of three independent experiments.
Figure 2. Statins prevent pro-inflammatory cytokine-induced MMP production in human 
articular cartilage. Human articular cartilage was cultured in serum-free medium in the presence of 
either medium alone, or medium containing IL-1α (0.5ng/ml) + OSM (10ng/ml) ± the indicated 
concentrations of simvastatin (Sim) or mevastatin (Mev) for 14 days. The levels of (A) MMP-1 and 
(B) MMP-13 in human cartilage cultured medium were assayed by immunoassay as described in 
Materials and Methods (mean ± S.D). All assays were performed in quadruplicate. Significance was 
analysed with respect to IL-1+OSM with statin compared to IL-1+OSM alone, where * p < 0.05, ** p
< 0.01, *** p < 0.001. Data are representative of three independent experiments. 
Figure 3. The effect of MA on the inhibition of pro-inflammatory cytokine-induced collagen 
release by simvastatin from bovine cartilage. (A) The mevalonic acid pathway.
Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) block the conversion from HMG-
CoA to mevalonic acid. Pathway intermediates used in this study are underlined. (B-D) Bovine nasal 
cartilage was cultured in serum-free medium in the presence of either medium alone, or medium 
containing IL-1α (0.5ng/ml) + OSM (10ng/ml) ± simvastatin (3 or 10µM) and the cholesterol 
biosynthesis pathway intermediate MA (100µM) for 14 days. (B) The levels of collagen fragments 
released into the medium were determined by measurement of hydroxyproline. Results shown are for 
the cumulative collagen release at day 14 of culture and expressed as a percentage of the total (mean ± 
S.D). (C) The levels of pro- and active collagenase activity in the media from cultured cartilage at day 
14 were measured (mean ± S.D). (D) As a measure of gelatinase activity, the day 14 culture media 
were analysed by gelatin zymography as described in Materials and Methods. All assays were 
performed in quadruplicate. Significance was analysed with respect to IL-1+OSM with statin 
18
compared to IL-1+OSM alone, where * p < 0.05, *** p < 0.001. Data are representative of three 
independent experiments.
Figure 4. The effect of MA on the inhibition of pro-inflammatory cytokine-induced MMP 
expression by simvastatin in bovine cartilage. Bovine nasal cartilage was cultured in serum-free 
medium in the presence of either medium alone, or medium containing IL-1α (0.5ng/ml) + OSM 
(10ng/ml) ± simvastatin (10µM) and cholesterol biosynthesis pathway intermediate MA (100µM) for 
7 days. Total RNA was isolated as described in Materials and Methods and subjected to real-time RT-
PCR for (A) MMP-1, (B) MMP-13, (C) MMP-3 and (D) MMP-9 mRNA expression normalised to 
18S (n = 3) (as indicated). Data are presented as fold induction relative to the basal expression and 
represent mean ± S.D. Significance was analysed with respect to IL-1+OSM with statin compared to 
IL-1+OSM alone, where * p < 0.05. Data are representative of three independent experiments.
Figure 5. The effect of simvastatin treatment on pro-inflammatory cytokine-induced MMP 
expression in human chondrocytes. HACs were stimulated with IL-1α (0.02ng/ml) + OSM 
(10ng/ml) for 24 hours ± (A) pre-treatment with simvastatin (10µM) for the indicated times or (B) pre-
treatment with simvastatin (10µM) for 48 hours in the presence of the cholesterol biosynthesis 
pathway intermediates MA (100µM), FPP (10µM), GGPP (10µM) or squalene (Sq) (50µM). Total 
RNA was isolated and subjected to real-time RT-PCR for MMP-1 and MMP-13 mRNA expression 
normalised to 18S (n = 4). Data are presented as fold induction relative to the basal expression and 
represent mean ± S.D. Significance was analysed with respect to IL-1+OSM with statin compared to 
IL-1+OSM alone, where * p < 0.05, ** p < 0.01, *** p < 0.001. Data are representative of at least 
three independent experiments.
Figure 6. The effect of simvastatin treatment on pro-inflammatory cytokine-induced signalling 
pathway activation in human chondrocytes. HACs were stimulated with IL-1α (0.02ng/ml) + OSM 
(10ng/ml) for 30 minutes ± (A and B) pre-treatment with simvastatin for 48 hours at the indicated 
concentrations, or (C and D) pre-treatment with simvastatin (10µM) for 48 hours in the presence of the 
cholesterol biosynthesis pathway intermediates MA (100µM), FPP (10µM) or GGPP (10µM). Total 
cellular protein was isolated as described in Materials and Methods, separated by SDS-PAGE and 
immunoblotted with the indicated antibodies. Data are representative of at least three independent 
experiments. Quantification data are shown as mean ± SEM percentage protein expression in 
comparison with IL-I+OSM alone levels for (A and B) 3 independent experiments and (C and D) 4 
independent experiments. Significance was analysed compared to IL-1+OSM alone, where * p < 0.05 
and † p < 0.01. 
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